Vitamin A Mist for Loss of Smell
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if aerosolized retinoic acid, a form of Vitamin A, can help restore the sense of smell lost due to COVID-19. Participants will receive various forms of retinoic acid, sometimes combined with Vitamin D, to identify the most effective treatment. The trial seeks individuals who have recovered from COVID-19 but still experience a loss or reduction in their sense of smell. This study could provide a new method to address the lingering effects of COVID-19 on smell. As a Phase 4 trial, the treatment has already received FDA approval and proven effective, and this research seeks to understand how it benefits more patients.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it excludes patients using nasal steroid sprays or irrigations. It's best to discuss your specific medications with the trial team.
What is the safety track record for these treatments?
Research shows that retinoic acid in spray form might help treat loss of smell caused by COVID-19. This treatment aids in repairing and growing smell receptors and cells in the nose. Retinoic acid, a type of Vitamin A, plays a role in fixing and growing these cells.
Past patients have generally found retinoic acid to be safe. It is also used for some skin conditions, where it is usually safe, though some people might experience mild side effects like dryness or irritation. These side effects often occur with higher doses or when taken orally or applied to the skin.
Researchers are exploring whether combining retinoic acid with Vitamin D enhances the treatment's effectiveness. Vitamin D is known to be safe and often supports bone health and the immune system.
This clinical trial is in an advanced stage, indicating that earlier studies have shown some evidence of safety. However, participants should discuss potential risks and benefits with the study team.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about these treatments for COVID-19-related loss of smell because they present a unique approach using aerosolized retinoic acid. Unlike standard treatments that may focus on supportive care or wait-and-see approaches, these treatments directly target the molecular pathways involved in the smell function by delivering retinoic acid, a potent vitamin A derivative, directly to the nasal passages. This method could potentially speed up recovery by addressing retinoic acid insufficiency, a novel target in anosmia treatment. Additionally, combining retinoic acid with vitamin D might enhance the overall therapeutic effect, offering a new avenue for those struggling to regain their sense of smell post-COVID-19.
What evidence suggests that this trial's treatments could be effective for COVID-19 anosmia?
Research suggests that a mist form of retinoic acid, a type of Vitamin A, might help treat the loss of smell caused by COVID-19. Studies have shown that it can improve the function of key proteins and cells in the nose needed for smelling. In this trial, participants will receive either Aerosolized 13 cis retinoic acid with Vitamin D or Aerosolized All trans retinoic acid with Vitamin D to test their effectiveness in restoring the sense of smell. Researchers are evaluating both forms for their potential to support the growth of smell-related nerve cells. These findings offer hope for those experiencing a loss of smell after COVID-19.12367
Who Is on the Research Team?
Mahmoud Elkazzaz, M.Sc of Biochemistry
Principal Investigator
Faculty of Science, Damietta university
Tamer Haydara, Ass/Prof of Internal medicine
Principal Investigator
Faculty of Medicine Kafrelshiekh university
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive aerosolized retinoic acid and Vitamin D therapy for post COVID-19 anosmia
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Aerosolized 13 cis retinoic acid plus Vitamin D
- Aerosolized All trans retinoic acid
- Aerosolized All trans retinoic acid plus Vitamin D
- Placebo/Control
- Standard therapy
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized all trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Standard therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amr kamel khalil Ahmed
Lead Sponsor
Kafrelsheikh University
Lead Sponsor
The First Hospital of Jilin University
Collaborator
Ministry of Health, Saudi Arabia
Collaborator
Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine , Jilin University China
Collaborator
Montefiore Health System and Albert Einstein College of Medicine, Newyork, United States of America (USA)
Collaborator
Faculty of Science, Kafrelsheikh University, Egypt.
Collaborator
Citations
Post-COVID-19 Anosmia and Therapies: Stay Tuned for New ...
Aerosolized retinoic acid may have an effective role in treating post-COVID-19 anosmia through upregulating ACE2 and STRA6 and regenerating OSNs ...
2.
reaganudall.org
reaganudall.org/clinical-trial/investigating-potential-role-aerosolized-retinoic-acid-potent-vitamin-metaboliteInvestigating the Potential Role of Aerosolized Retinoic
Aerosolized retinoic acidwill have an effective role in treating post COVID-19 anosmia (loss of smell) viaupregulating ACE2, STRA 6 and regenerating of ...
3.
researchgate.net
researchgate.net/publication/359118791_13_cis_retinoic_acid_improved_the_outcomes_of_COVID-19_patients_A_randomized_clinical_trial13 cis retinoic acid improved the outcomes of COVID-19 ...
... Aerosolized retinoic acid may have an effective role in treating post-COVID-19 anosmia through upregulating ACE2 and STRA6 and regenerating OSNs expressing ...
13 cis retinoic acid improved the outcomes of COVID-19 ...
All patients who received 13 cis retinoic acid noticed a high improvement (P<0.001), and the mean value for clinical improvement was 16.3±4.5 ...
5.
researchgate.net
researchgate.net/publication/371110408_Post-COVID-19_Anosmia_and_Therapies_Stay_Tuned_for_New_Drugs_to_Sniff_OutPost-COVID-19 Anosmia and Therapies: Stay Tuned for ...
The drug therapies that appear more effective and promising are PEA-LUT and Cerebrolysin. The other interesting drugs are 13-cis-retinoic acid ...
Post COVID-19 Anosmia (Loss of Smell) (DBCOND0142042)
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .
Post-COVID-19 Anosmia and Therapies: Stay Tuned for ...
... 13 cis retinoic acid);. Response 28: the sentence was entirely rewritten:”They evaluated the administration of dexamethasone 6 mg/day per os ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.